Benechill, a privately held San Diego medical device company, said July 20 it obtained $13.5 million in Series C financing, led by new investor HealthCap of Stockholm. Series A and B investors MedVenture Associates, NGN Capital and the Solon Foundation also participated in the latest round.
Benechill, which is developing products in the therapeutic hypothermia arenas, said it will use the proceeds to fund early commercialization of its Rhinochill device.
Rhinochill is a noninvasive, portable device used to treat patients with cardiac arrest, stroke or head injuries, but is still under investigation in this country, the company said.
Click here for more information about HealthCap
.
